Andrzej Jakubowiak, MD, PhD | Authors

Jakubowiak on Responses in Subgroups of Patients With Myeloma Who Received Cilta-Cel

January 14, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, dives into response outcomes in different patient subsets of the phase 1/2b CARTITUDE-1 trial of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

Jakubowiak Talks CAR T-Cell Therapy in Heavily Pretreated Myeloma at 2021 ASH

January 10, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, describes how CAR T-cell therapy for patients with heavily pretreated myeloma has the potential significantly impact response and survival outcomes.

Jakubowiak Talks Daratumumab Quadruplet Therapy and the GRIFFIN Study at 2021 ASH

January 07, 2022

In an interview at the 2021 ASH Annual Meeting, Andrzej Jakubowiak, MD, PhD, talks about daratumumab-based quadruplet therapies being evaluated in clinical trials and the potential impact they’ll have on the multiple myeloma treatment landscape.